Skip to Main Content

KMAP BULLETIN: Preferred Drug List Update – November 2026

Date: 10/23/26

KMAP GENERAL BULLETIN 26187 (PDF)

Effective with dates of service on or after November 1, 2026, the following medications will be added or moved to Preferred:

  • Adalimumab-aaty | PFS and pen
  • Adalimumab-ryvk (Labeler 51759) | Pen
  • Alyftrek™ (vanzacaftor/tezacaftor/deutivacaftor) | Tablet
  • Foundayo™ (orforglipron) | Tablet
  • Ingrezza® (valbenazine) | Capsule
  • Ingrezza Sprinkle® (valbenazine) | Capsule
  • Starjemza™ (ustekinumab-hmny) | PFS and vial
  • Xolair® (omalizumab) | PFS, vial


Effective with dates of service on or after November 1, 2026, the following medications will be added or moved to Non-preferred:

  • Adalimumab-bwwd | PFS and pen
  • Austedo® (deutetrabenazine) | Tablet
  • Austedo XR® (deutetrabenazine) | Tablet XR
  • Avtozma® (tocilizumab-anoh) | Pen, PFS, Vial
  • Awiqli® (insulin icodec-abae) | Prefilled pen
  • Dexlyt™ (dexamethasone 0.25 mg) | Tablet
  • Doxycycline hyclate 75mg | Capsule, Tablet
  • Enbrace HR® (multi-supplement) | Softgel capsule
  • Icotyde™ (icotrokinra) | Tablet
  • Prenate Enhance® (multi-supplement) | Softgel capsule
  • Prenate Restore® (multi-supplement) | Softgel capsule
  • Rhapsido® (remibrutinib) | Tablet
  • Tonmya™ (cyclobenzaprine) | Sublingual tablet
  • Tyruko® (natalizumab-sztn) | Vial
  • Yuflyma® (adalimumab-aaty) | PFS and pen


Effective with dates of service on or after November 1, 2026, the following medications will be removed from Preferred Drug List (PDL):

  • Pancreaze® (pancrelipase) | Capsule 

 

A Grandfather Prior Authorization (PA) process is in place for KanCare patients, according to the following guidelines:

  • For members currently taking a maintenance drug that newly requires a PA, and the member has been 80% adherent, the member will receive a Grandfather PA.
  • For members who have filled a maintenance drug that newly requires a PA, and the member has filled the medication once or with an adherence rate of less than 80%, the member will not be given a Grandfather PA.
  • For members currently taking medications considered  non-maintenance (acute or seasonal treatments) (For example, acne agents, muscle relaxants, NSAIDs, antihistamines, etc.), no Grandfather PA will be given.

 

Reference the Prior Authorization – Clinical Criteria page on the  Kansas Department of Health and Environment (KDHE) website for Clinical PA information.

Note: The effective date of the policy is November 1, 2026. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.